Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4775092 | 1.00 | TSPO (0.35) | TSPOMAPTGGPS1PDE4BNAMPT | |
| SCHEMBL1814098 | 0.92 | HPGD (0.36) | MAPTPDE4BNPC1HPGDRAB9A | |
| SCHEMBL1814100 | 0.92 | HPGD (0.36) | MAPTPDE4BNPC1HPGDRAB9A | |
| SCHEMBL4772339 | 0.87 | AKR1C4 (0.36) | PDE4BAKR1C4AKR1C3CYP11B1CYP11B2 | |
| SCHEMBL4772334 | 0.87 | AKR1C4 (0.36) | PDE4BAKR1C4AKR1C3CYP11B1CYP11B2 | |
| SCHEMBL4772747 | 0.87 | CYP11B1 (0.36) | TSPOGGPS1PDE4BNAMPTCYP11B1 | |
| SCHEMBL4772522 | 0.85 | SMN1; SMN2 (0.36) | MAPTNPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4772526 | 0.85 | SMN1; SMN2 (0.36) | MAPTNPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL5306841 | 0.85 | SIGMAR1 (0.31) | SIGMAR1 | |
| SCHEMBL4772554 | 0.85 | SIGMAR1 (0.31) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459451-B2 | e.g. 1-Ethyl-4-(5-methyl-3-pyridyl)-6-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid; phosphodiesterase (PDE)-IV inhibitor or tumor necrosis factor (TNF)- alpha antagonist; autoimmune diseases, antidepressant, anxiolytic agent; polychondritis, scleroderma, fibrosis, arthritis, Alzheimer's disease | ASTELLAS PHARMA INC. (JP) | 2008-12-02 | — | — | US | disclosed |
| EP-1763528-B1 | PYRAZOLOPYRIDINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2008-11-26 | — | — | EP | disclosed |
| EP-1763528-A1 | PYRAZOLOPYRIDINE DERIVATIVES | Astellas Pharma Inc. (JP) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006004188-A1 | PYRAZOLOPYRIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2006-01-12 | — | — | WO | disclosed |
| US-20060004003-A1 | Pyrazolopyridine derivatives | ASTELLAS PHARMA INC. (JP) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004003-A1 | Pyrazolopyridine derivatives | PDE4A, PDE3B, PDE5A | TSPO 4169/4885MAPT 2816/4885GGPS1 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.